XTL Biopharmaceuticals plans extraordinary meeting

XTL Biopharmaceuticals Ltd. reported that it will hold an Extraordinary General Meeting of Shareholders on February 17, 2026 at 4:00 p.m. (Israel time) in Tel Aviv, Israel.

Accepted by SEC EDGAR 01/13/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. reported that it will hold an Extraordinary General Meeting of Shareholders on February 17, 2026 at 4:00 p.m. (Israel time) in Tel Aviv, Israel. The meeting will take place at the offices of its legal counsel, Amit, Pollak, Matalon & Co., on Raoul Wallenberg Street.

To support the meeting, the company is providing a Notice and Proxy Statement, as well as a Proxy Card that allows holders of ordinary shares to vote without attending in person. These documents, furnished as exhibits to the report, describe the proposals to be voted on and explain how shareholders can participate and cast their votes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is XTLB (XTL Biopharmaceuticals Ltd.) holding its Extraordinary General Meeting?

The Extraordinary General Meeting of Shareholders is scheduled for February 17, 2026 at 4:00 p.m. (Israel time).

Where will XTLB’s Extraordinary General Meeting of Shareholders take place?

The meeting will be held at the offices of Amit, Pollak, Matalon & Co., APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.

What documents did XTL Biopharmaceuticals provide for the 2026 Extraordinary General Meeting?

The company furnished a Notice and Proxy Statement for the Extraordinary General Meeting as Exhibit 99.1 and a Proxy Card for holders of ordinary shares as Exhibit 99.2.

How can XTLB shareholders vote if they do not attend the Extraordinary General Meeting in person?

Shareholders holding ordinary shares may vote without attending in person by using the Proxy Card provided as Exhibit 99.2.

What information is included in XTLB’s Notice and Proxy Statement for the Extraordinary General Meeting?

The Notice and Proxy Statement describe the proposals to be voted upon, the procedure for voting in person or by proxy, and various other details related to the meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of January 2026

001-36000 (Commission File Number)

XTL Biopharmaceuticals Ltd.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan, Israel, 5257346

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On January 13 2026, XTL Biopharmaceuticals Ltd. (the “Company”) announced that it will hold an Extraordinary General Meeting of Shareholders on Tuesday, February 17, 2026 at 4:00 p.m. (Israel time) at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel. In connection with the meeting, the Company furnishes the following documents:

	1.	A copy of the Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1;
	2.	A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2; and

Exhibit Index

Exhibit No.		Description
99.1		Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders
99.2		Proxy Card for holders of ordinary shares with respect to the Company’s Extraordinary General Meeting of Shareholders

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XTL BIOPHARMACEUTICALS LTD.
Date: January 13, 2026	/s/ Noam Band
	Noam Band Chief Executive Officer

2